SNPs for Genes Encoding the Mitochondrial Proteins Sirtuin3 and Uncoupling Protein 2 Are Associated With Disease Severity, Type 2 Diabetes, and Outcomes in Patients With Pulmonary Arterial Hypertension and This Is Recapitulated in a New Mouse Model Lacking Both Genes

Yongneng Zhang, MD; Sotirios D. Zervopoulos, PhD; Aristeidis E. Boukouris, MD; Maria Areli Lorenzana-Carrillo, MSc; Bruno Saleme, BSc; Linda Webster, MSc; Yongseng Liu, MSc; Alois Haromy, MSc; Seyed Amirhossein Tabatabaei Dakhili, PhD; John R. Ussher, PhD; Gopinath Sutendra, PhD; Evangelos D. Michelakis, MD

BACKGROUND: Isolated loss-of-function single nucleotide polymorphisms (SNPs) for SIRT3 (a mitochondrial deacetylase) and UCP2 (an atypical uncoupling protein enabling mitochondrial calcium entry) have been associated with both pulmonary arterial hypertension (PAH) and insulin resistance, but their collective role in animal models and patients is unknown.

METHODS AND RESULTS: In a prospective cohort of patients with PAH (n=60), we measured SNPs for both SIRT3 and UCP2, along with several clinical features (including invasive hemodynamic data) and outcomes. We found SIRT3 and UCP2 SNPs often both in the same patient in a homozygous or heterozygous manner, correlating positively with PAH severity and associated with the presence of type 2 diabetes and 10-year outcomes (death and transplantation). To explore this mechanistically, we generated double knockout mice for Sirt3 and Ucp2 and found increasing severity of PAH (mean pulmonary artery pressure, right ventricular hypertrophy/dilatation and extensive vascular remodeling, including inflammatory plexogenic lesions, in a gene dose-dependent manner), along with insulin resistance, compared with wild-type mice. The suppressed mitochondrial function (decreased respiration, increased mitochondrial membrane potential) in the double knockout pulmonary artery smooth muscle cells was associated with apoptosis resistance and increased proliferation, compared with wild-type mice.

CONCLUSIONS: Our work supports the metabolic theory of PAH and shows that these mice exhibit spontaneous severe PAH (without environmental or chemical triggers) that mimics human PAH and may explain the findings in our patient cohort. Our study offers a new mouse model of PAH, with several features of human disease that are typically absent in other PAH mouse models.

Key Words: insulin resistance ■ mitochondria ■ plexogenic arteriopathy ■ pulmonary arterial hypertension ■ vascular remodeling ■ vascular smooth muscle cells

See Editorial by Lajoie et al.
CLINICAL PERSPECTIVE

What Is New?
• We found a provocative correlation between the loss-of-function SNPs of sirtuin3 and uncoupling protein 2 (both encode mitochondrial proteins) with the severity of disease in patients with pulmonary arterial hypertension (PAH), as well as an association with the presence of type 2 diabetes (a previously described feature of patients with PAH that remains unexplained) and outcomes (death or transplantation).
• We also created a novel mouse model (sirtuin3 and uncoupling protein 2 double-knockout) of PAH in which to explore our clinical data, and we found that it has more features of human PAH than any previously described rodent model of PAH.
• This is the first mouse model of PAH with spontaneous and extensive plexogenic lesions (the sine qua non of human PAH).

What Are the Clinical Implications?
• Our mouse model supports our provocative clinical data in our cohort and is directly relevant to a subgroup of patients with PAH carrying more than 1 loss-of-function SNPs in genes encoding mitochondrial proteins, particularly for those patients who carry them in both alleles.
• These are relatively common SNPs in the general population and thus they could be further explored as potential biomarkers in Precision Medicine studies.
• Also, since mouse models of PAH have been criticized for the lack of important clinical features of human PAH (including the mild increase in pulmonary artery pressures and the lack of plexogenic lesions), our new mouse PAH model is important for the translational research field of PAH, strengthening the role of genetic mouse models for mechanistic studies.

Nonstandard Abbreviations and Acronyms
- CO: cardiac output
- PAH: pulmonary arterial hypertension
- PASMCs: pulmonary artery smooth muscle cells
- PHT: pulmonary hypertension
- PVR: pulmonary vascular resistance
- TAPSE: tricuspid annular plane systolic excursion
- Ucp2: uncoupling protein 2

Pulmonary arterial hypertension (PAH) is characterized by pulmonary arterial remodeling that results in lumen obliteration, raising the pulmonary vascular resistance (PVR). While initially this leads to right ventricular (RV) hypertrophy, it then advances to RV dilation and death from RV failure.\textsuperscript{1,2} The vascular wall cells in the remodeled pulmonary arteries are characterized by activation of many transcription factors (eg, nuclear factor of activated T-cells c2, hypoxia inducible factor 1a, etc) that promote proliferation; and by a multifactorial suppression of mitochondrial function that promotes apoptosis resistance in a cancer-like manner.\textsuperscript{1} Our proposed metabolic theory of PAH suggests that such a mitochondrial suppression is a critical and early event that has the potential to also activate many of the transcription factors implicated in PAH.\textsuperscript{3–5} It could also promote the inflammation that has recently been shown to play a central role in the disease (eg, the remodeled pulmonary arteries are surrounded by many activated inflammatory cells).\textsuperscript{3,4,6} Inhibition of mitochondrial oxidative phosphorylation (glucose oxidation) is an early and necessary event in T cell activation.\textsuperscript{7} There is also evidence that patients with PAH have features of the metabolic syndrome and insulin resistance (without necessarily being obese).\textsuperscript{8} In fact, in skeletal muscle biopsies in patients with PAH, there is evidence of mitochondrial dysfunction (downregulation of mitochondrial enzymes and upregulation of glycolytic enzymes).\textsuperscript{9} In animals with PAH, decreased respiration in skeletal muscle was shown to be present early in the development of PAH.\textsuperscript{10} This suggests that a systemic metabolic disturbance may affect the whole body in a patient with PAH, although the vascular pathology is specific to the pulmonary arteries (compared with systemic vessels). This is why knocking out mitochondrial proteins in the whole animal (as opposed to cell or tissue-specific KO) is clinically relevant.

Indeed, KO mice lacking either Sirt3 (sirtuin3)\textsuperscript{11} (a major mitochondrial deacetylase) or Ucp2 (uncoupling protein 2)\textsuperscript{12,13} (an atypical uncoupling protein that mostly facilitates calcium entry into the mitochondria) developed spontaneous pulmonary hypertension (PHT) and vascular remodeling. However, as is commonly the case with mice PHT models, the increase in PA pressure was mild and the mice did not develop plexogenic lesions, perhaps the most typical pathology finding in human PAH (anarchic proliferation of diverse vascular and inflammatory cells causing near-complete obliteration of the vascular lumen).\textsuperscript{14} In fact, the only model that reliably exhibits plexiform lesions and severe PAH with high mortality is the rat in response to Sugen (a vascular endothelial growth factor inhibitor) plus hypoxia, although the plexiform lesions appear only at the late stages of the disease.\textsuperscript{15} A potential limitation of that model is that a nonphysiologic drug has to be used, confounding the interpretation of...
the data, particularly on the role of endothelial cells. Currently, there is no mouse model that develops predictably and commonly plexogenic lesions.

Loss of Sirt3 or Ucp2 expression or function leads to hyperacetylation of mitochondrial proteins and enzymes (inhibiting their function\textsuperscript{11,16} and decreased intramitochondrial calcium\textsuperscript{17} (inhibiting the function of Ca\textsuperscript{++}-dependent enzymes such as pyruvate dehydrogenase, the gatekeeping enzyme in glucose oxidation\textsuperscript{10})), respectively. This results in mitochondrial hyperpolarization and decreased production of diffusible mitochondrial reactive oxygen species (such as H\textsubscript{2}O\textsubscript{2}) causing apoptosis resistance.\textsuperscript{3–5} Along with the decreased production of diffusible metabolites (such as α-ketoglutarate) in pulmonary vascular cells, these redox changes promote activation and nuclear translocation of pro-proliferative transcription factors, such as hypoxia inducible factor 1α (even in the absence of hypoxia) or nuclear factor of activated T-cells c2, which have been implicated in the pathogenesis of PAH.\textsuperscript{3–5}

We recently conducted a small clinical trial to test the response of patients with PAH to a metabolic modulator, showing potential beneficial effects.\textsuperscript{18} To study the subgroup of patients who did not respond to dichloroacetate, a drug that has been shown to reactivate mitochondrial suppression by inhibiting pyruvate dehydrogenase kinase (a mitochondrial enzyme that inhibits pyruvate dehydrogenase), we performed genotyping. We found that several patients had loss of function SNPs in SIRT3 (rs11246020) and UCP2 (uncoupling protein 2) (rs659366) in 1 or both alleles, and in fact some patients carried both single nucleotide polymorphisms (SNPs) in either 1 or both alleles.\textsuperscript{18} Clinically, the presence of these relatively common SNPs has been associated with the metabolic syndrome and type 2 diabetes in humans\textsuperscript{16,19–22} (ie, conditions in which a generalized metabolic abnormality is present throughout the body). The SIRT3 SNP affects the catalytic domain of the sirtuin3 protein, inhibiting its activity by up to 34%, whereas the UCP2 SNP affects the promoter of the gene, resulting in decreased UCP2 mRNA levels.\textsuperscript{16,22} Either way, the patients who carry these SNPs, which are not in linkage disequilibrium, would have abnormal mitochondrial function and may be predisposed to more severe PAH, particularly when both SNPs are present.

First, we hypothesized that these 2 SIRT3 and UCP2 SNPs may be prevalent in patients with PAH and may be correlated with the severity of disease, the presence of type 2 diabetes, and perhaps the outcomes of the disease. Second, to mechanistically explore this hypothesis, we generated mice that lack both Sirt3 and Ucp2 and hypothesized that they may develop severe PHT and perhaps recapitulate more features of human PAH than other commonly used rodent PHT models. We specifically aimed to determine whether they would develop spontaneous and severe PHT at a young age (without the use of external triggers such as hypoxia or Sugen), as well as inflammatory plexogenic lesions.

**METHODS**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Our work with human clinical data and human blood as well as our work with mice were performed with permission from the University of Alberta Human Research Ethics Board (HREB) and Animal Care and Use Committee (ACUC), respectively.

**SNP Genotyping Assay**

Genomic DNA was extracted from buffy coat using FlexiGene DNA Kit (QIAGEN) following the manufacturer’s instruction. DNA samples were quantified with a Nanodrop Spectrophotometer (ND-8000) and normalized to a concentration of 6.5 ng/μL. Samples (50 ng per each) were genotyped by TaqMan SNP Genotyping Assays for rs11246020 (SIRT3) and rs659366 (UCP2), and processed and read on the Droplet Digital PCR QX200 (Bio-Rad) according to the manufacturer’s protocol. Each sample was partitioned into 20,000 discrete droplets and after amplification, each droplet was analyzed individually using a 2-color detection system (FAM and VIC). Amplifications were carried out as follows: at 94 °C for 10 minutes, followed by 40 cycles at 94 °C (30 s), 60 °C (1 minute, ramp rate: 2–3 °C per s); followed by holding at 98 °C (10 minutes), and holding at 4 °C.

**Sirt3 and Ucp2 Mutant Genotyping**

Mice were genotyped by polymerase chain reaction (PCR) using genomic DNA isolated from ear notching biopsies as described by Jackson Laboratories. Sirt3 mutant mice have deletion of exons 2 to 3, which abolishes gene function. A combination of 2 forward primers (1 for mutant, sequence: TAC TGA ATA TCA GTG GGA ACG and 1 for wild type, sequence: CTT CTG CCG CTC TAT ACA CAG) along with 1 common reverse primer (sequence: TGC AAC AAG GCT TTA TCT TCC) was used to detect the wild-type allele (562 bp) and the mutant allele (200 bp, deletion of exons 2–3 result in a smaller fragment). The Sirt3 heterozygous mice are positive for both alleles (wild type 562 bp and mutant 200 bp). The targeted Ucp2 mutant mice have an insertion of a PGK-NEO cassette replacing exons 3 to 7 to create the larger mutant allele. Two sets of primers are used in combination to identify wild type (forward primer sequence: CCG TTC TGG GTA CCA TCC TA, reverse primer sequence: GCT CTG
AGC CCT TGG TGT AG and mutant mice (forward primer sequence: CTT GGG TGG AGA GCC TAT TC, reverse primer sequence: AGG TGA GAT GAC AGG AGA TC). The mutant allele (that expresses the larger PGK-NEO cassette) is expressed at 280 bp, while the wild-type allele (which does not express the PGK-NEO cassette) is expressed at a lower 156 bp. The Ucp2 heterozygous mice are positive for both alleles (mutant 280 bp and wild type 156 bp). PCRs were carried out on a MasterCycler PCR Thermal Cycler (Eppendorf Cat # 5345) by direct amplification of the DNA from ear notching biopsies with the use of Phire Tissue Direct PCR Master Mix (ThermoFisher Scientific Cat # F170) following the manufacturer’s protocol. Amplifications were carried out as follows: at 94 °C for 5 minutes, followed by 10 cycles at 94 °C (20 s), 65 °C (15 s, −0.5 °C per cycle decrease), 68 °C (10 s); followed by 32 cycles at 98 °C (15 s), 60 °C (15 s), 72 °C (10 s); finishing at 72 °C (2 minutes) and holding at 4 °C.

RNA Isolation and Quantitative Reverse Transcription PCR
mRNA was isolated using Qiazol (Qiagen). mRNA isolated from muscle and lung was added to a microc- ell plate with TaqMan probes and reagents. Primers were purchased from Thermo Fisher Scientific (Sirt3 Mm01275637_g1, Ucp2 Mm00627599_m1).

Cell Culture
Pulmonary artery smooth muscle cells (PASMCs) isolation was performed as previously described.11,12 Briefly, PASMCs from wild-type (WT), Sirt3−/−-Ucp2+/−, Sirt3−/−-Ucp2−/−, and Sirt3+/−-Ucp2−/− mice were freshly isolated from intrapulmonary arteries (>fourth division), with an enzymatic cocktail containing papain (1 mg/mL) (Sigma Aldrich), dithiothreitol (0.5 mg/mL) (Sigma Aldrich), collagenase I (0.8 mg/mL) (Worthington), and bovine serum albumin (0.8 mg/mL) (Sigma-Aldrich). PASMCs were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco) with 10% fetal bovine serum (Sigma-Aldrich) and 1% penicillin/streptomycin (Gibco) at 9% CO2. Passages 2 to 4 PASMCs were used for all experiments.

Mitochondrial Respiration Measurements
PASMCs were seeded to Seahorse V7 tissue culture plates overnight for analysis of oxygen consumption and extracellular acidification using the Seahorse XFe 24 Analyzer (Agilent Technologies). Measurements were taken at baseline. Oxygen consumption rate and extracellular acidification rate were measured and normalized to total protein amounts isolated from each well.

Immunoblots
Tissues were collected and immunoblotting was performed as previously described.11,12 Antibodies and dilutions: sirtuin3 (Cell Signaling Technology, 5490) 1:1000, Ucp2 (Santa Cruz, sc-6525) 1:300, p-AKT (Ser473) (Cell Signaling Technology, 4060T) 1:1000, AKT (Cell Signaling Technology, 4691) 1:3000, and β-Actin (Santa Cruz sc81178) 1:2000.

Confocal Imaging
Immunofluorescence staining was performed as previously described11,12,18,23 and imaging was performed using a Zeiss LSM-710 model, equipped with an Airyscan module (Carl Zeiss). Antibodies used were alpha smooth muscle actin (Abcam, ab5694), von Willebrand factor (Abcam, ab11713), CD4 (Invitrogen, LS14004182), Ki67 (Abcam, ab166677), nuclear factor of activated T-cells c2 (Abcam, ab2722), hypoxia inducible factor 1α (Abcam, ab3028), and Y705p-STAT3 (Cell Signaling Technology, 9131). All antibodies used for immunofluorescence were diluted in 1:100 and all secondary antibodies in 1:1000. Apoptosis was measured using the Apoptag Apoptosis Detection Kit for TUNEL (Invitrogen) and the Dead Cell Apoptosis Kit with Annexin V FITC and Propidium iodide (Invitrogen). The mitochondrial membrane potential was measured by staining live PASMCs with 20 nmol/L tetramethyl-rhodamine methyl-ester perchlorate (Invitrogen) and 500 nmol/L Hoechst 33342 (Invitrogen) for 30 minutes at 37 °C. The mitochondrial reactive oxygen species were measured by staining live PASMCs with 5 μmol/L MitoSOX (Invitrogen) and 500 nmol/L Hoechst 33342 in nonserum media for 15 minutes at 37 °C, and then cells were washed and replaced with regular media.

Echocardiography
Echocardiography was performed as previously described.11,12,24,25 Mice were anesthetized with isoflurane and maintained a heart rate of 350 to 450 beats per minute and the Vevo 3100 High Resolution Imaging System (VisualSonics, Toronto, Canada) was used. RV thickness, RV end-diastolic diameter, and tricuspid annular plane systolic excursion (TAPSE) were recorded in the M-Mode. TAPSE was calculated by measuring the vertical movement of the tricuspid annulus between end-diastole and end-systole in the 4-chamber view, reflecting the longitudinal contraction of the RV. Cardiac output (CO) was calculated after determining the pulmonary artery diameter, pulmonary artery velocity time integral, and heart rate using the formula: \[ \text{CO} = 7.85 \times \text{PAD}^2 \times \text{pulmonary artery velocity time integral} \times \text{heart rate} / 10000 \]. Images with heart rate <350 were excluded from the analysis.
Hemodynamic Measurements
Mice were initially anesthetized with 3% to 4% isoflurane and maintained with 2% during procedures. Mice underwent hemodynamic studies as previously described\textsuperscript{11,12,24,25} and were euthanized subsequently. A modified Millar catheter (microtip, 1.4F, Millar Instruments) was advanced through the jugular vein in closed-chest animals into right atrium (RA), RV, and PA; and RA pressure, RV pressure, and mean PA pressure were recorded. Left ventricular end-diastolic pressure was recorded by retrograde advancement of the catheter from the carotid artery into the left ventricle (Power Lab, with Chart software 5.4, ADInstruments).

Pulmonary Vascular Medial Wall Thickness and Pulmonary Arteriole Muscularization
Frozen lung samples were prepared after injecting OCT through the trachea to expand the lung. Lung sections (5 \textmu m) were stained using hematoxylin and eosin stain for histology, and smooth muscle actin and von Willebrand factor (endothelial cell marker) for immunofluorescence. For measuring medial wall thickness, vessels >40 and <300 \textmu m were identified and measured at the 2 ends of the shortest external diameter of the pulmonary arteries, and the average was taken (\((2 \times \text{wall thickness/external diameter}) \times 100\)). For measuring muscularization, vessels (<40 \textmu m) were classified as fully (100%), partially, or nonmuscularized (0%), based on the percentage of von Willebrand factor surrounded by smooth muscle actin in each vessel.

In Vivo Assessment of Glucose Homeostasis
Glucose and insulin tolerance tests were performed in mice fasted overnight or after a 6-hour fast, following which IP glucose (2 g/kg) or insulin (0.5 U/kg) was administered. Blood glucose measurements were assessed via tail whole-blood at the end of the fast, followed by samples at various time points postglucose or insulin administration, using the Contour Next blood glucose monitoring system (Bayer) as previously described.\textsuperscript{26} Plasma was also collected during the glucose tolerance test from tail whole-blood at the 0- and 30-minute time points for the assessment of circulating insulin levels, using a commercially available enzyme-linked immunosorbent assay kit (Alpco Diagnostics) as previously described.\textsuperscript{26}

Statistical Analysis
All statistical analyses were performed on STATA (StataCorp LLC, TX). Values are expressed as mean±SEM. The use of parametric or nonparametric tests was decided after assessment of normal distribution of the values by the Shapiro–Wilk normality test. For parametric tests, we used 2-tailed, unpaired Student t test to assess statistical significance between 2 groups, and multiple groups were compared using 1-way ANOVA or 2-way repeated-measures ANOVA followed by a Bonferroni post hoc analysis. For nonparametric tests, Mann–Whitney U test was used for comparisons between 2 groups and Kruskal–Wallis test was used to compare multiple groups. Nonparametric correlation analysis of the clinical data was performed using the Spearman correlation coefficient. Significance for all statistical testing was considered to be \(P<0.05\).

RESULTS
To study the presence of SIRT3 and UCP2 SNPs, we used a small (n=60) but well-characterized prospective cohort of patients with PAH that had agreed to participate in our clinical database and also offer blood for our biobank, at the time of their referral, over the past 10 years. These consisted of associated PAH (mainly patients with autoimmune collagen vascular diseases such as scleroderma or history of anorectic drugs use) and idiopathic PAH. All patients underwent right heart catheterization, echocardiography, pulmonary function testing, V/Q scan and lung computed tomography scans, as well as extensive bloodwork, so that all the potentially secondary causes of PHT were excluded and the patients could accurately be diagnosed with PAH. Patients were not included if they had a severe disease other than PAH, including cancer, evidence of significant systemic vascular disease, morbid obesity, or renal failure. The hemodynamics shown in Table reflect the first catheterization, before the initiation of PAH therapies. All the patients were followed at least 3 times a year and all received a protocol-driven initiation of PAH therapies, which included the following: phosphodiesterase type 5 inhibitors as a first line of therapy; addition of an endothelin receptor antagonist if 3 to 4 months later the 6-minute walk test remained below 350 m; and addition of a prostacyclin analogue if at any point the 6-minute walk dropped below 200 m with clinical evidence of RV failure resistant to diuretics. Table also shows the therapies for each patient, at the last review of the 10-year database (ie, June 2020). The common, protocol-driven therapeutic approach and the exclusion of significant comorbidities at inclusion allowed us to follow outcomes (death or lung transplantation) in our cohort. All the deaths shown in Table were considered, to the best of our knowledge, to be a direct result of PAH worsening and right heart failure.

Digital PCR was utilized with primers for both the SNP variant and the WT versions of each of the SIRT3 and UCP2 genes. We used an SNP score method that
Table. Single nucleotide polymorphism (SNP) Scores for UCP2/SIRT3 and Clinical Information Related to the PAH Cohort

| Age, y | Sex | Type | mPAP (mm Hg) | PVR (dyn·s/cm²) | Type 2 DM | Meds | Outcomes | SIRT3 | UCP2 | SNP score |
|--------|-----|------|--------------|----------------|-----------|------|----------|-------|-------|-----------|
| 1      | 63  | F    | aPAH 40      | 429            | Y          | P, E | Dead     | V/Wt  | V/Wt  | 2         |
| 2      | 62  | F    | aPAH 52      | 665            | Y          | P    | Alive    | Wt/Wt | V/Wt  | 1         |
| 3      | 77  | M    | iPAH 54      | 804            | N          | P, E, Pr | Alive  | Wt/Wt | V/Wt  | 1         |
| 4      | 78  | M    | iPAH 52      | 752            | N          | P, E | Dead     | Wt/Wt | V/Wt  | 1         |
| 5      | 74  | M    | aPAH 47      | 683            | Y          | P, E | Dead     | Wt/Wt | V/Wt  | 2         |
| 6      | 48  | M    | iPAH 61      | 905            | N          | P, E, Pr | Alive  | Wt/Wt | Wt/Wt | 1         |
| 7      | 66  | F    | aPAH 48      | 1376           | N          | P, E, Pr | Dead   | Wt/Wt | V/V   | 2         |
| 8      | 68  | F    | aPAH 40      | 695            | N          | P, E, Pr | Alive  | Wt/Wt | Wt/Wt | 1         |
| 9      | 64  | F    | aPAH 28      | 597            | N          | P    | Alive    | Wt/Wt | V/Wt  | 1         |
| 10     | 53  | M    | iPAH 64      | 1429           | N          | P, E | Alive    | Wt/Wt | Wt/Wt | 1         |
| 11     | 67  | F    | aPAH 39      | 281            | N          | P    | Alive    | Wt/Wt | Wt/Wt | 0         |
| 12     | 52  | F    | aPAH 70      | 609            | N          | P, E, Pr | Alive  | Wt/Wt | Wt/Wt | 1         |
| 13     | 46  | F    | aPAH 68      | 838            | Y          | P, Pr | Alive    | Wt/Wt | V/V   | 2         |
| 14     | 45  | F    | aPAH 44      | 451            | N          | P, E | Dead     | Wt/Wt | Wt/Wt | 1         |
| 15     | 73  | M    | iPAH 53      | 640            | N          | P, E | Dead     | Wt/Wt | Wt/Wt | 2         |
| 16     | 55  | M    | aPAH 59      | 812            | N          | P, E, Pr | Alive  | Wt/Wt | V/Wt  | 2         |
| 17     | 70  | M    | aPAH 60      | 580            | N          | P, E, Pr | Dead   | Wt/Wt | V/V   | 2         |
| 18     | 63  | F    | aPAH 54      | 567            | N          | P, Pr | Alive    | Wt/Wt | Wt/Wt | 0         |
| 19     | 36  | M    | iPAH 68      | 1011           | N          | P, Pr | Transpl  | V/Wt  | V/Wt  | 2         |
| 20     | 48  | F    | aPAH 51      | 1502           | N          | P, Pr | Dead     | Wt/Wt | V/Wt  | 1         |
| 21     | 51  | F    | aPAH 42      | 463            | N          | P, E | Alive    | Wt/Wt | Wt/Wt | 0         |
| 22     | 48  | F    | iPAH 69      | 709            | N          | P, E | Alive    | Wt/Wt | Wt/Wt | 1         |
| 23     | 24  | F    | iPAH 37      | 348            | N          | P, E | Alive    | Wt/Wt | Wt/Wt | 0         |
| 24     | 57  | M    | iPAH 55      | 775            | N          | P, E, Pr | Alive  | Wt/Wt | Wt/Wt | 0         |
| 25     | 72  | M    | iPAH 60      | 584            | Y          | P    | Dead     | Wt/Wt | V/Wt  | 1         |
| 26     | 74  | M    | iPAH 48      | 417            | N          | P    | Dead     | Wt/Wt | V/Wt  | 1         |
| 27     | 40  | F    | iPAH 48      | 950            | N          | P, E | Alive    | Wt/Wt | Wt/Wt | 0         |
| 28     | 22  | F    | iPAH 48      | 1097           | N          | P, E, Pr | Alive  | V/Wt  | Wt/Wt | 1         |
| 29     | 70  | F    | iPAH 58      | 987            | N          | P, Pr | Alive    | Wt/Wt | V/V   | 2         |
| 30     | 58  | M    | iPAH 94      | 1387           | N          | P, Pr | Dead     | V/V   | Wt/Wt | 2         |
| 31     | 31  | M    | aPAH 29      | 434            | N          | P    | Alive    | V/Wt  | Wt/Wt | 1         |
| 32     | 58  | M    | aPAH 27      | 316            | N          | P    | Alive    | Wt/Wt | Wt/Wt | 0         |
| 33     | 42  | M    | iPAH 65      | 592            | N          | P, E | Dead     | Wt/Wt | V/Wt  | 1         |
| 34     | 70  | F    | iPAH 62      | 527            | Y          | P, Pr | Dead     | Wt/Wt | Wt/Wt | 0         |
| 35     | 53  | M    | iPAH 52      | 770            | N          | P, E | Dead     | V/Wt  | V/Wt  | 2         |
| 36     | 43  | F    | iPAH 34      | 465            | N          | P    | Alive    | Wt/Wt | V/V   | 2         |
| 37     | 36  | F    | iPAH 52      | 710            | N          | P, E | Dead     | Wt/Wt | Wt/Wt | 0         |
| 38     | 71  | F    | aPAH 31      | 480            | N          | P, E | Dead     | Wt/Wt | Wt/Wt | 0         |
| 39     | 73  | F    | aPAH 40      | 493            | N          | P, E, Pr | Dead   | Wt/Wt | V/Wt  | 1         |
| 40     | 57  | M    | aPAH 37      | 617            | N          | P, B | Dead     | Wt/Wt | V/Wt  | 1         |
| 41     | 49  | M    | aPAH 39      | 512            | N          | P    | Alive    | Wt/Wt | Wt/Wt | 0         |
| 42     | 51  | F    | aPAH 29      | 336            | N          | P, E | Dead     | Wt/Wt | V/Wt  | 1         |
| 43     | 56  | F    | iPAH 69      | 850            | N          | P, E, Pr | Dead   | Wt/Wt | Wt/Wt | 0         |
| 44     | 31  | F    | iPAH 26      | 357            | N          | P    | Alive    | Wt/Wt | Wt/Wt | 0         |
| 45     | 74  | F    | aPAH 43      | 311            | Y          | P, E | Dead     | Wt/Wt | V/Wt  | 1         |
| 46     | 31  | F    | iPAH 70      | 738            | N          | P, E | Alive    | Wt/Wt | Wt/Wt | 0         |
(Continued)
we previously described, by which a score of 0 was given if both alleles were WT; a score of 1 if 1 of the SNPs was present in a heterozygous manner; a score of 2 if both SNPs were present in a homozygous manner; and a score of 3 if only 1 SNP was present in a homozygous and the other was present in a heterozygous manner (Table; Figure 1A). Table lists the SNP (ie, gene variant) in both alleles for both Sirt3 and Ucp2 genes. We found that the majority of patients had an SNP score of 1, many had a score of 2, and 1 patient had a score of 3 (Table). A nonparametric correlation analysis using the Spearman coefficient revealed a weak but statistically significant positive correlation between the PVR (mean PAP-PAWP/CO) and the SNP score (Figure 1B), meaning the increase of PVR is a dosage effect of gene alleles. We found that type 2 diabetes was more prevalent in patients with an SNP score of 1 and 2 to 3 (attributable risk from the presence of the SNPs 58% and 75%, respectively), and the same was true for death/transplantation (attributable risk 29% and 47%), compared with patients with an SNP score of 0 (Table; Figure 1B). We realize the small size of our single center cohort does not allow us to conclude that there is either a true or a causal association with disease severity, type 2 diabetes, or negative outcomes, but this was a motivation to explore this provocative association mechanistically with an animal model.

We generated a double knockout colony from a double heterozygous colony that was initially generated by crossing heterozygote Sirt3+/− mice (129/Sv background) with Ucp2+/− mice (C57BL6 background), both of which are commercially available and previously published by our group.11,12 We then crossed double heterozygous mice to obtain a Mendelian mix of Sirt3+/−-Ucp2+/−, Sirt3−/−-Ucp2+/−, Sirt3−/−-Ucp2−/−, and Sirt3+/−-Ucp2−/− mice. We crossed the double heterozygous subcolony for 10 generations before we established a stable new mixed background WT mouse (WT, Sirt3−/−-Ucp2−/−) and after that, we started crossing and studying littermate mice (Figure S1A through S1C). We chose this approach (rather than backcrossing toward 1 of the 2 backgrounds) because it better reflects the genetic variability of our patients with PAH. Sirt3−/−-Ucp2−/− mice were viable at birth (ie, no embryonic lethality), and they also fit the predicted Mendelian ratio, suggesting that double loss of Sirt3 and Ucp2 is not required for embryogenesis.

By the third to fourth month of age, both male and female mice showed clinical evidence of disease (ie, decreased activity, agitation, and decreased feeding). Echocardiography and close-chest right heart catheterization (via the jugular vein) at 3- to 4-months-old mice revealed PHT with elevated systolic and mean arterial pressures, increased right atrial pressure, decreased cardiac output, RV hypertrophy and RV dilatation (both by echocardiography and at euthanasia) and decreased systolic RV function (by TAPSE in echocardiography) (Figure 2A and 2B). Absence of any increase in left ventricular end-diastolic pressure (Figure S2) and macroscopic/histology evidence of lung parenchymal abnormalities suggested that this was PAH. Importantly and as hypothesized, there was a dose–response between the degree of gene loss and the severity of PAH, as the worse PAH was found in Sirt3+/−-Ucp2−/− mice, less in the Sirt3−/−-Ucp2+/− or Sirt3+/−-Ucp2−/− mice, and less in the Sirt3+/−-Ucp2+/− mice, while all showed higher pressures than the WT mouse (Figure 2A). Even

Table 1. (Continued)

| Age, y | Sex | Type | mPAP (mm Hg) | PVR (dyn·s/cm²) | Type 2 DM | Meds | Outcomes | SIRT3 | UCP2 | SNP score |
|-------|-----|------|-------------|---------------|-----------|------|----------|-------|------|-----------|
| 48    | 70  | F    | iPAH        | 51            | 710       | N    | P, E    | Alive | V/Wt | Wt/Wt     | 1       |
| 49    | 60  | F    | iPAH        | 59            | 648       | Y    | P, E    | Dead  | Wt/Wt | V/Wt      | 1       |
| 50    | 48  | M    | aPAH        | 86            | 1067      | N    | P, E    | Dead  | Wt/Wt | V/Wt      | 1       |
| 51    | 44  | F    | aPAH        | 25            | 309       | N    | P       | Dead  | Wt/Wt | V/Wt      | 1       |
| 52    | 50  | F    | aPAH        | 60            | 832       | N    | P, E    | Alive | V/Wt | V/V       | 3       |
| 53    | 71  | M    | iPAH        | 42            | 640       | N    | P, E    | Dead  | Wt/Wt | Wt/Wt     | 0       |
| 54    | 54  | F    | aPAH        | 45            | 577       | N    | P, E    | Dead  | Wt/Wt | Wt/Wt     | 0       |
| 55    | 47  | F    | iPAH        | 58            | 756       | N    | P, E, Pr| Dead  | V/V  | Wt/Wt     | 2       |
| 56    | 24  | F    | iPAH        | 56            | 912       | N    | P, E, Pr| Transpl| Wt/Wt| Wt/Wt     | 0       |
| 57    | 27  | F    | iPAH        | 50            | 1050      | N    | P, E, Pr| Dead  | V/V  | Wt/Wt     | 2       |
| 58    | 19  | M    | aPAH        | 40            | 334       | N    | P       | Alive | Wt/Wt| Wt/Wt     | 0       |
| 59    | 61  | F    | iPAH        | 57            | 800       | N    | P, E, Pr| Dead  | Wt/Wt| V/V       | 2       |
| 60    | 36  | F    | iPAH        | 52            | 710       | Y    | P, E    | Alive | Wt/Wt| Wt/Wt     | 0       |

aPAH indicates associated pulmonary arterial hypertension; DM, diabetes mellitus; E, endothelin receptor antagonists; iPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary artery pressure; P, phosphodiesterase type 5 inhibitors; Pr, prostacyclin analogues; PVR, pulmonary vascular resistance; V, variant SNP; and Wt, wild type (normal).
at this young age of 3 to 4 months, the mice had clear right ventricular hypertrophy (RVH), and decreased systolic RV function and RV dilatation was mostly present at the Sirt3−/−-Ucp2+/− or Sirt3+/−-Ucp2−/− mice (Figure 2A). We also performed the Masson’s trichrome staining to the right ventricles to measure fibrosis. These data showed that Sirt3−/−-Ucp2+/− (3 allele-KO) and Sirt3−/−-Ucp2−/− (double KO) mice have a significant increase of fibrosis, compared with WT controls (Figure S3). Moreover, the mortality (as assessed by Kaplan–Meier survival curve) was significantly increased in the Sirt3−/−-Ucp2−/− mice, compared with WT (Figure S4). Although most of the mice studied were male, at least 2 female mice were included in each of the groups shown in Figure 2A. No difference was detected between male and female mice and the data were expressed as 1 group for each study.

Lung histology showed the presence of extensive vascular remodeling, with the worst shown in Sirt3−/−-Ucp2−/− and Sirt3+/−-Ucp2−/− or Sirt3+/−-Ucp2−/−, in keeping with the hemodynamic data. There was an increase in percent medial thickness in medium-sized pulmonary arteries (40–100 µm) (Figure 3A) and increased muscularization of the small-sized vessels (<40 µm), shown in both hematoxylin and eosin staining and confocal microscopy immunohistochemistry, using smooth muscle actin to mark smooth muscle cells and von Willebrand factor to mark the endothelium (Figure 3B). More importantly, there were
extensive plexogenic lesions in the pulmonary vessels of the Sirt3−/−-Ucp2−/− and Sirt3−/−-Ucp2+/− or Sirt3+/−-Ucp2−/− mice (Figure 4). The remodeled pulmonary arterioles also had increased levels of the proliferation marker Ki67 (Figure S5).

An unanswered question in the PAH field is the mechanism of the plexogenic arteriopathy and particularly whether this is downstream or upstream to the increase in pressure. Performing closed chest right heart catheterization in young mice is challenging and very difficult in mice of 2 months of age. We managed to perform reliable catheterization in the three 2-month-old mice/group and we found that the Sirt3−/−-Ucp2−/− mice had established plexogenic arteriopathy despite the fact that the PA pressure (at least at rest) was within normal levels and similar to the WT mice (Figure S6).

We then tested whether there was increased presence of inflammatory cells within and around the remodeled pulmonary vessels by staining the lungs with a marker of Treg cells (CD4), which have been directly implicated in the pathogenesis of PAH, although whether they promote injury or they participate in the healing response remains unclear.27,28 Similar to the
vascular remodeling degree, the \textit{Sirt3}^{-/-}-\textit{Ucp2}^{-/-} and \textit{Sirt3}^{-/-}-\textit{Ucp2}^{+-} or \textit{Sirt3}^{+/-}-\textit{Ucp2}^{-/-} mice exhibited a large pulmonary vascular infiltration with CD4$^+$ T cells, compared with lungs from WT mice (Figure S7).

We then isolated and cultured PASMCs from the intrapulmonary pulmonary arteries of these mice (>fourth division) and we showed that even in in vitro conditions they maintained their proliferative phenotype, with the \textit{Sirt3}^{-/-}-\textit{Ucp2}^{-/-} and \textit{Sirt3}^{-/-}-\textit{Ucp2}^{+-} or \textit{Sirt3}^{+/-}-\textit{Ucp2}^{-/-} PASMCs expressing more Ki67, higher nuclear levels of the pro-proliferative master transcription factors hypoxia inducible factor 1$\alpha$ and nuclear factor of activated T cells c2, and a higher ratio of nuclear/cytoplasmic of Y705p-STAT3, than PASMCs from the WT mice (Figure 5A, Figure S8). Under serum starvation (0.1%), the \textit{Sirt3}^{-/-}-\textit{Ucp2}^{+-} and \textit{Sirt3}^{-/-}-\textit{Ucp2}^{+-} or \textit{Sirt3}^{+/-}-\textit{Ucp2}^{+-} PASMCs exhibited less apoptosis compared with the WT cells, measured with the TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling) and Annexin V assays (Figure 5B and Figure S9). We have previously shown that proliferative PASMCs from animals with PAH had more hyperpolarized mitochondria (measured by tetramethyl-rhodamine methyl-ester perchlorate) and produced less mitochondrial reactive oxygen species (measured by MitoSox).\textsuperscript{11,12,25,29} This was confirmed in these cells as well, with the \textit{Sirt3}^{-/-}-\textit{Ucp2}^{-/-} and \textit{Sirt3}^{-/-}-\textit{Ucp2}^{+-} or \textit{Sirt3}^{+/-}-\textit{Ucp2}^{-/-} PASMCs exhibiting higher mitochondrial membrane potential (higher tetramethyl-rhodamine methyl-ester perchlorate fluorescence) and lower levels of mitochondrial reactive oxygen species (lower MitoSox fluorescence) (Figure 6A). The increased mitochondrial potential contributes to the suppression of mitochondria-dependent apoptosis and is consistent with a suppression of mitochondrial function, as we have previously shown in both PAH PASMCs and cancer cells.\textsuperscript{18,30,31} Thus, we measured respiration and

---

**Figure 3.** Pulmonary vascular remodeling in mice heterozygote or homozygote to the loss of both \textit{Sirt3} and \textit{Ucp2}.

\textbf{A}, Representative images (hematoxylin and eosin staining) from lungs of all the mice groups along with mean data of percent medial wall thickness (MWT) of pulmonary arterioles (40–300 $\mu$m) are shown. ****$P<0.0001$ compared with WT mice. These comparisons were done post hoc (Bonferroni) since the overall 1-way ANOVA for the groups was significant. n=35 arteries/group. 

\textbf{B}, Representative confocal images of small arterioles (<40 $\mu$m) and mean data of percent muscularization are shown. DAPI indicates 4',6-diamidino-2-phenylindole (nuclear stain); SMA indicates smooth muscle actin; Ucp2, uncoupling protein 2; vWF, von Willebrand factor (marking endothelial cells), and WT, wild type.. The mean percent muscularization is shown to the right. n=50 arteries/group.
Zhang et al. 
SNPs of Sirt3 and Ucp2 Are Associated With PAH

glycolytic rates in PASMCs. As expected, we found that Sirt3−/−-Ucp2−/− and Sirt3−/−-Ucp2+/− or Sirt3+/−-Ucp2−/− PASMCs had lower respiration rates and higher glycolytic rates compared with WT PASMCs, using the SEAHORSE platform (Figure 6B).

Last, we assessed for signs of insulin resistance in Sirt3−/−-Ucp2−/− mice, which demonstrated marked elevations in blood glucose levels in response to a glucose tolerance test, compared with WT mice (Figure 7A). The glucose intolerance in Sirt3−/−-Ucp2−/− mice was associated with no change in circulating insulin levels, suggesting that there is skeletal muscle insulin resistance, rather than pancreatic dysfunction. Accordingly, the ability of insulin to lower blood glucose was markedly diminished in Sirt3−/−-Ucp2−/− mice during an insulin tolerance test, compared with WT mice (Figure 7A). Moreover, Akt phosphorylation was impaired in the gastrocnemius muscle collected from Sirt3−/−-Ucp2−/− mice during the insulin tolerance test, whereas the Akt phosphorylation increased appropriately in WT gastrocnemius muscle (Figure 7B). This finding also supported insulin resistance in Sirt3−/−-Ucp2−/− mice, likely because of impaired insulin signaling immediately downstream from the insulin receptor.

Figure 4. Plexogenic arteriopathy in mice lacking both Sirt3 and Ucp2.
Representative pictures of lung histology (top) and confocal immunohistochemistry of small pulmonary arteries from Sirt3+/−-Ucp2−/−, Sirt3+/−-Ucp2+/−, and Sirt3−/−-Ucp2−/− mice. Arrows indicate plexogenic lesions in top 5 images. DAPI indicates 4',6-diamidino-2-phenylindole (nuclear stain); Sirt3, sirtuin3; SMA, smooth muscle actin; Ucp2, uncoupling protein 2; and vWF, von Willebrand factor (marking endothelial cells).
DISCUSSION

Our work supports the metabolic theory of PAH, which suggests that mitochondrial suppression is central to the pathogenesis of PAH, and not secondary or downstream to other abnormalities described in PAH pathogenesis.3,4 There are 2 important and novel findings in our work, discussed below.

First, we describe a somewhat unexpected high prevalence of loss-of-function SNPs in 2 genes encoding mitochondrial proteins in a small but well-characterized prospective cohort of patients with PAH, in whom we collected blood at the time of their original assessment and we followed over the past 10 years. We found a provocative association between these SNPs and the severity of PAH or the presence of type 2 diabetes (previously described feature of patients with PAH that remains unexplained8,9) and outcomes (death or transplantation), which clearly needs to be prospectively studied in larger and independent studies, before it can be claimed to be either true or causal (Table; Figure 1B). Moreover, PAH affects more women than men, but the prognosis of male patients is worse than that of female patients. This is in keeping with our data since male patients with PAH have a higher SNP score than female patients. For example, 33% of male patients have an SNP score 2 to 3 compared with 23% in female patients, while 36% of female patients have

Figure 5. Proliferative and anti-apoptotic phenotype in cultured PASMCs from mice heterozygote or homozygote to the loss of both Sirt3 and Ucp2.

A. Increased intranuclear levels of HIF1α, NFATc2, and Ki67 in PASMCs from mice lacking Sirt3 and Ucp2 compared with PASMCs from WT mice. ***P<0.0001 (Bonferroni) compared with the WT PASMCs, following 1-way ANOVA, n=150 cells/group (HIF1α and NFATc2), n=240 cells/group (Ki67) (from 3 mice/group).

B. Increased resistance to apoptosis (less TUNEL-positive PASMCs) in response to serum starvation for 48 hours is shown in PASMCs from mice lacking Sirt3 and Ucp2 compared with PASMCs from WT mice. ***P<0.0001 (Bonferroni) compared with the WT PASMCs, following 1-way ANOVA, n=240 cells/group (from 3 mice/group).

AFU indicates absolute fluorescence units; DAPI, 4',6-diamidino-2-phenylindole (nuclear stain); HIF1α, hypoxia inducible factor 1α; NFATc2, nuclear factor of activated T cells 2; PASMCs, pulmonary artery smooth muscle cells; sirt3, sirtuin3; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling; Ucp2, uncoupling protein 2; and WT, wild type.
Zhang et al SNPs of Sirt3 and Ucp2 Are Associated With PAH

an SNP score 0 compared with 23% of male patients; also, a higher SNP score correlates positively with PAH severity and outcomes (death and transplantation). However, the overall small sample size does not allow for any conclusive statements when it comes to outcomes, other than hypothesis generation.

The fact that all patients received the same protocol-driven therapeutic approach, the absence of significant comorbidities upon entering the cohort, along with the fact that PAH therapies are not known to affect survival,² allow us to report this association with outcomes. Importantly, we previously showed that patients with PAH with a high SNP score for these 2 SNPs had more inhibited pyruvate dehydrogenase function and mitochondrial respiration than patients without SNPs, studied in lungs immediately after they were explanted at transplant surgery.¹⁸ The SIRT3 SNP variant (rs11246020) that affects the enzyme’s catalytic activity has been shown to decrease the enzymatic activity of Sirt3 in patient carriers.¹⁶ Carriers of the UCP2 SNP (rs659366) that affects the promoter of the gene have a variant-dependent decrease in UCP2 mRNA in the subcutaneous fat (ie, the SNP homozygotes have the lowest level, followed by the heterozygotes and the patients carrying both WT type alleles).²² Yet another study showed that the carriers of the same SNP had increased levels of Ucp2 mRNA in the intra-abdominal fat, suggesting that the regulation of Ucp2 is tissue

Figure 6. Metabolic remodeling in PASMCs from mice lacking Sirt3 and Ucp2.
A, Staining with the mitochondrial tracer TMRM and MitoSox shows that PASMCs from Sirt3−/−-Ucp2+/−, Sirt3+/−-Ucp2−/−, and Sirt3−/−-Ucp2−/− mice have higher mitochondrial membrane potential and lower production of mitochondrial-derived ROS, respectively, compared with mitochondria from WT PASMCs. ****P<0.0001 (Mann–Whitney U test) compared with the WT PASMCs, n=50 cells/group (3 experiments). B, SEAHORSE measurements of respiration (OCR) and ECAR (indicative of glycolysis) show that PASMCs from Sirt3−/−-Ucp2+/− and Sirt3−/−-Ucp2−/− mice have suppressed OCR (ie, suppressed mitochondrial function) and increased ECAR (ie, secondary increase in glycolysis) compared with PASMCs from WT mice. For OCR: *P=0.0196, **P=0.0025; for ECAR: *P=0.0016, ****P<0.0001 (Bonferroni) compared with the WT PASMCs, following 1-way ANOVA. n=12 measurements from 3 mice/group. AFU indicates absolute fluorescence units; DAPI, 4',6-diamidino-2-phenylindole (nuclear stain); ECAR, extracellular acidification rate; OCR, oxygen consumption rate; PASMCs, pulmonary artery smooth muscle cells; ROS, reactive oxygen species; sirt3, sirtuin3; TMRM, tetramethylrhodamine methyl ester; Ucp2, uncoupling protein 2; and WT, wild type.
dependent and may also be affected by additional factors. In summary, although from our small sample size we cannot be certain that this association will stand when tested in other multicenter and larger cohorts, we believed it deserved mechanistic exploration in an animal model that mimics the loss of function of Sirt3 and Ucp2.

Second, we created a novel mouse model of PAH in which to explore our clinical data, and we found that it has more features of human PAH than in previously described rodent models. First, the severe PHT found in mice lacking Sirt3 and Ucp2 is spontaneous, occurs at a young age, and leads to definitive objective features of RV failure (ie, increased RA pressure, decreased CO, dilatation of the RV, and a significant decrease in RV function) (studied in vivo with TAPSE) (Figure 2A). Second, after following the strict pathology criteria that have been described for these plexogenic lesions in both the rat Sugen/hypoxia model and humans, we found these mice had frequent

Figure 7. Insulin resistance in mice lacking Sirt3 and Ucp2 and an overall proposed mechanism for the diverse effects of SIRT3 and UCP2 loss in humans and mice with PAH.

A, Following starvation for 16 h, the glucose levels in the blood Sirt3−/−-Ucp2−/− are higher following glucose administration at time 0, compared with WT mice (glucose 2 g/kg IP), but the blood insulin levels are not different (GTT). The glucose levels decrease less after insulin administration (0.5 U/kg IP) following 6 h starvation (the ITT was performed 5 d after the GTT), compared with WT mice. AUC (for GTT test) and AAC (for ITT test) are shown in the bar graphs. Differences were determined by the use of an unpaired 2-tailed Student t test (AUC and AAC) or a 2-way repeated-measures ANOVA followed by Bonferroni post hoc analysis (GTT and ITT). *P<0.0173, **P=0.0035 compared with WT mice, n=5 to 6 mice/group. B, Skeletal muscle (gastrocnemius) was removed at time 0 and 30 minutes during the ITT. Fold increase in p-AKT/AKT shows that while the WT muscles showed the expected increase in Akt phosphorylation, the Sirt3−/−-Ucp2−/− muscle did not show any change. A representative immunoblot is shown along with the mean data. *P=0.0331 (t test) compared with WT mice, n=4 mice/group. C, A proposed mechanism of how a primary mitochondrial abnormality can explain the presence of PAH, vascular inflammation, and insulin resistance in human and mouse PAH (see Discussion). AAC indicates areas above the curves; AUC, areas under the curves; GTT, glucose tolerance test; HIF1α, hypoxia inducible factor 1α; ITT, insulin tolerance test; mROS, mitochondrial reactive oxygen species; NFATc2, nuclear factor of activated T cells C2; PAH, pulmonary arterial hypertension; PASMC, pulmonary artery smooth muscle cell; Sirt3, sirtuin3; SNPs: single nucleotide polymorphisms; Ucp2, uncoupling protein 2; and WT, wild type.

B
plexogenic lesions, even at the age of 2 months, before the establishment of hemodynamic evidence of PHT (at least at rest) (Figure 4 and Figure S6). There is no other mouse model that shows frequent and predictable plexogenic lesions. This finding may offer a potential answer to the question of whether the plexogenic lesions follow or precede the increase in PA pressures. If anything, existing models (ie, the Sugen/hypoxic rat model) had suggested that these lesions appear late in the disease when PHT is already severe\textsuperscript{16} and human data (because of the lack of biopsies at earlier stages of the disease) cannot provide an answer.\textsuperscript{14} Third, we found an increased infiltration of the pulmonary arterioles with CD4\textsuperscript{+} T cells (Figure S7). Recently, the role of inflammation in PAH has emerged as central to the pathogenesis of PAH.\textsuperscript{6,27} The lack of these 2 mitochondrial proteins from T cells themselves is predicted to facilitate their activation, since inhibition of oxidative phosphorylation is both necessary and precedes T cell activation.\textsuperscript{7} Thus, we cannot determine whether the increased infiltration of T cells in the pulmonary vessels of these mice is a result of signaling from the lung microenvironment or it reflects T cell activation in the bone marrow. On the other hand, considering the presence of these SNPs in patients, the same applies to patients having suppressed mitochondrial function throughout the body. Fourth, the insulin resistance found in the Sirt3\textsuperscript{−/−}-Ucp2\textsuperscript{−/−} tochondrial function throughout the body. Fourth, the same applies to patients having suppressed mitochondrial function (with no other factor). This finding is similar to what is reported for the pancreatic dysfunction), but this appears to depend on other factors, including insulin resistance and skeletal muscle mitochondrial suppression, reported previously by other groups.\textsuperscript{8,9} May actually be patients with higher SNP scores for SIRT3 and UCP2 allelic SNPs. Sirt3 KO mice are predisposed to insulin resistance in keeping with our data.\textsuperscript{16} Ucp2 KO mice are also predisposed to diabetes because they exhibit suppressed glucose-induced insulin secretion\textsuperscript{35} (although in our case we found insulin resistance and not diabetes relating to pancreas dysfunction), but this appears to depend on mice background.\textsuperscript{36} Regardless of their background, the fact that severe PAH coexists with insulin resistance in the same animal with a global mitochondrial deficiency directly supports our clinical finding that the presence of these SNPs is associated with the presence of type 2 diabetes in patients with PAH. It also allows us to speculate that this association is potentially causal. In fact, the skeletal muscle from the offspring of patients with type 2 diabetes has insulin resistance because of an inherited defect in oxidative phosphorylation,\textsuperscript{37} a finding similar to what is reported for the skeletal muscle of patients with PAH.\textsuperscript{9}

Another important aspect of our work is that, while in our patient cohort the correlation of SNP score with the severity of PAH (PVR, outcomes) was weak (but statistically significant), our mice showed a very strong and positive gene dose-dependent relation between the loss of Sirt3/Ucp2 and the increase in PA pressure, as well as the worsening of RV failure (RV end-diastolic diameter, RA pressure, CO, and TAPSE) and vascular remodeling (Figure 2A). This supports our clinical data showing a correlation between the SNP score and PVR. Our animal ethics committee did not allow us to perform death end-point studies, but the degree of RV failure and the clinical signs of the Sirt3\textsuperscript{−/−}-Ucp2\textsuperscript{−/−} and Sirt3\textsuperscript{−/−}-Ucp2\textsuperscript{+/−} or Sirt3\textsuperscript{+/−}-Ucp2\textsuperscript{−/−} mice (decreased activity/withdrawal, decreased appetite, and irritability) suggested a significant burden of disease requiring euthanasia. Thus, our mice data also support the association of these SNPs with outcomes (death or transplantation) in our clinical cohort.

Since mouse models of PAH have been criticized for the lack of important clinical features of human PAH (including the mild increase in PA pressures and the lack of plexogenic lesions), our new mouse PAH model may prove to be helpful in the field. Mice are far more useful in molecular and genetic studies than other animal models. In the future, our mice could be crossed with other KO or transgenic mice that lack genes that either worsen or protect from PAH, further improving our tools for the study of PAH, a disease that is clearly multifactorial.

Two-month-old Sirt3\textsuperscript{−/−}-Ucp2\textsuperscript{−/−} mice have plexogenic lesions but normal PA pressures. Therefore, it appears that even in the early phase of the disease (2-month-old), the lack of Ucp2 and Sirt3 still induces a hyperproliferative phenotype of PASMCs, pulmonary artery endothelial cells (PAECs), and fibroblasts, which are components of plexogenic lesion (we stained for both PASMCs and PAECs). The observed proliferation of PAECs may be a repair response to an initial loss/injury of PAEC, as some theories suggest for early PAH. Our data show, however, that at this very young age there is already evidence of proliferation throughout the vascular wall, although the possibility of increased loss of PAEC at an even earlier stage cannot be excluded. We have previously summarized in original publications and reviews the potential mechanisms that are downstream of mitochondrial suppression (both in PAH and cancer), which explain both the proliferation and anti-apoptotic phenotype in PASMCs, including the mechanism of activation of critical transcription factors that have been shown to be activated in human and animal PAH\textsuperscript{24,25} (Figure 7C). In addition to loss of Sirt3 and Ucp2, other factors have been shown to contribute to the mitochondrial suppression in PAH PASMCs, including endoplasmic reticulum stress,\textsuperscript{24,25} or abnormalities in mitochondrial fission/fusion.\textsuperscript{36,38} Our current work now further suggests that mitochondrial suppression is not only “permissive” for the development of PAH, as we
have previously suggested in our metabolic theory of PAH, but also may be actively causal, since these mice recapitulate many features of human PAH.

We also previously proposed that although mitochondrial abnormalities may be present throughout the body, the fact that the vascular phenotype is restricted to the lung vasculature may have to do with the fact that there are differences between pulmonary vascular mitochondria and systemic vascular mitochondria (a fact that may also explain why hypoxic pulmonary vasoconstriction is a specific feature of the pulmonary and not systemic circulation), making cells in pulmonary microvessels more responsive earlier to mitochondrial abnormalities, than cells in systemic vessels. Although we did not study that in detail, we did not observe systemic vascular abnormalities, at least enough to affect left ventricular end-diastolic pressure. This allowed us to “diagnose” PAH in these mice, but we cannot be certain that these mice would not develop systemic vascular diseases if they were to survive to grow older.

Since Sirt3 KO mice have also been shown to develop pulmonary fibrosis, it is possible that our Sirt3−/− Ucp2−/− mice may develop worsening pulmonary fibrosis with age, although they did not have anatomic evidence of fibrosis or hypoxemia at the time that we studied them. If these mice were to develop pulmonary fibrosis with age (either directly or secondary to inflammation) they would still be relevant to the clinical associated PAH because of collagen vascular diseases such as scleroderma, which is characterized by pulmonary fibrosis in addition to PAH.

However, this study also has some limitations. First, the size of the PAH patient cohort is small, so we were not able to analyze the subgroups of SNP score 2 to 3 to show whether there are any differences between SIRT3 SNP and UCP2 SNP. Second, to support the human data, our mouse model used gene knockout (KO) rather than a mouse expressing the human SNP. This is extraordinarily difficult and even more difficult is to express 2 human SNPs. On the other hand, the double KO mice allowed us to also study the lack of genes in a variety of homozygote/heterozygote combinations, allowing us to assess “gene dose-dependent” associations, which strengthen the causality aspect of our mechanism. Third, we cannot rule out primary effects of Ucp2 or Sirt3 loss on the RV myocardium. However, because the left ventricular size and function were not affected, this is somewhat unlikely. In addition, the mild RV enlargement and dysfunction that we noted in our young mice is not out of proportion with the degree of PAH that we measured.

In conclusion, our mouse model supports our provocative clinical data in our cohort and is directly relevant to a subgroup of patients with PAH carrying more than 1 loss-of-function SNPs in genes encoding mitochondrial proteins, particularly those that carry them in both alleles.

ARTICLE INFORMATION

Received December 9, 2020; accepted June 22, 2021.

Affiliations

Department of Medicine (Cardiology), Faculty of Medicine and Dentistry (Y.Z., S.D.Z., A.E.B., M.A.L., B.S., L.W., Y.L., A.H., G.S., E.D.M.) and Faculty of Pharmacy and Pharmaceutical Sciences (S.A.T.D., J.R.U.), University of Alberta, Edmonton, Alberta, Canada.

Sources of Funding

Zhang is supported by a graduate scholarship from the Li Ka Shing Sino-Canadian Exchange Program. Lorenzana-Carrillo is supported by the Government of Mexico CONACYT Scholarship for Doctoral Studies Abroad. Saleme is supported by a graduate scholarship from Alberta Innovates. Ussher is supported by a Canada Research Chair. Sutendra is supported by an Alberta Innovates Translational Health Chair in Cardio-Oncology, and a National and Alberta New Investigator Award from Heart and Stroke Foundation of Canada. Michelakis is supported by a Canada Research Chair, and this work was supported by the Heart and Stroke Foundation of Canada, and Canadian Institutes of Health Research Foundation grants to Michelakis.

Disclosures

None.

Supplementary Material

Figures S1–S9

REFERENCES

1. Sutendra G, Michelakis ED. Pulmonary arterial hypertension: challenges in translational research and a vision for change. Sci Transl Med. 2013;5:208sr5. doi: 10.1126/scitranslmed.3005428
2. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society Inc, and the Pulmonary Hypertension Association. Circulation. 2009;119:2250–2294. doi: 10.1161/CIRCULATIONAHA.109.192230
3. Paulin R, Michelakis ED. The metabolic theory of pulmonary arterial hypertension. Circ Res. 2014;115:148–164. doi: 10.1161/CIRCRESAHA.115.301130
4. Sutendra G, Michelakis ED. The metabolic basis of pulmonary arterial hypertension. Cell Metab. 2014;19:558–573. doi: 10.1016/j.cmet.2014.01.004
5. Dromparis P, Michelakis ED. Mitochondria in vascular health and disease. Annu Rev Physiol. 2013;75:95–126. doi: 10.1146/annurev-physiol-030212-183804
6. Rabinovich M, Guignabert C, Humbert M, Nicollis MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res. 2014;115:165–175. doi: 10.1161/CIRCRESAHA.113.301141
7. Macver NJ, Michalek RD, Rathmel JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol. 2013;31:259–283. doi: 10.1146/annurev-immunol-032712-095956
8. Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM, Rabinovich M, Doyle RL. Insulin resistance in pulmonary arterial hypertension, Eur Respir J. 2009;33:318–324. doi: 10.1183/09031936.0000508
9. Malenfant S, Potus F, Fournier F, Breuil-Bonnet S, Pfieger A, Bourassa S, Tremblay E, Némé B, Droit A, Bonnet S, et al. Skeletal muscle protonic signature and metabolic impairment in pulmonary hypertension. J Mol Med (Berl). 2015;93:573–584. doi: 10.1007/s00109-014-1244-0
10. Enache I, Charles AL, Bouitbir J, Favret F, Zoll J, Metzger D, Oswald-Mammosser M, Geny B, Charloux A. Skeletal muscle mitochondrial dysfunction precedes right ventricular impairment in experimental
23. Sutendra G, Kinnaird A, Dromparis P, Paulin R, Stenson TH, Haromy A. J Am Heart Assoc. 2014;20:827–839. doi: 10.1016/j.ahj.2014.08.011

24. Dromparis P, Paulin R, Stenson S, Michelakis ED. Uncoupling protein 2 deficiency mimics the effects of hypoxia and endoplasmic reticulum stress on mitochondria and triggers pseudo-hypoxia pulmonary vascular remodeling and pulmonary hypertension. Circ Res. 2013;113:126–136. doi: 10.1161/CIRCRESAHA.112.300699

25. Sutendra G, Dromparis P, Wright P, Bonnet S, Haromy A, Hao Z. Clin Sci (Lond). 2017;132:151–161. doi: 10.1042/cs20170714

26. Al Batran R, Gopal K, Capozzi ME, Chahade JJ, Saleme B, Tabatabaei-Dakhil SA, Greenwell AA, Niu J, Almutairi M, Byrne NJ, et al. Pimozide alleviates hyperglycemia in diet-induced obesity by inhibiting skeletal muscle ketone oxidation. Cell Metab. 2020;31:919–928. doi: 10.1016/j.cmet.2020.03.017

27. Qiu H, He Y, Ouyang F, Jiang P, Guo S, Guo Y. The role of regulatory T cells in pulmonary arterial hypertension. J Am Heart Assoc. 2019;8:e014201. doi: 10.1161/JAHA.119.014201

28. Tamasiusienie R, Tian W, Dhillon G, Wang L, Sung YK, Gera L, Patterson AJ, Agrawal R, Rabinovitch M, Ambler K, et al. Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res. 2011;109:867–879. doi: 10.1161/CIRCRESAHA.110.236927

29. McMurtry MS, Archer SL, Altiere DC, Stenson B, Haromy A, Harry G, Puttagunta L, Michelakis ED. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest. 2005;115:1479–1491. doi: 10.1172/JCI23203

30. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thebaud B, Bonnet S, Haromy A, Harry G, Moudgil R, McMurtry MS, et al. An abnormal mitochondrial-hypoxia inducible factor-talpka-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation. 2006;113:2830–2841. doi: 10.1161/CIRCULATIONAHA.105.609008

31. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven L, Maguire C, Gammer TL, Mackey JR, Fulton D, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010;2:31ra34. doi: 10.1126/scitranslmed.3000677

32. Virtue S, Vidal-Puig A. GTTs and ITTs in mice: simple tests, complex answers. Nat Metabol. 2021. doi: 10.1038/s42255-021-00414-7

33. Esterbauer H, Schneitler C, Oberkofler H, Ebenbichler C, Paulweber B, Sandhofer F, Ladurner G, Heli E, Strosberg AD, Patsch JR, et al. A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet. 2002;31:178–183. doi: 10.1038/ng9911

34. Pietra GQ, Capron F, Stewart S, Levine O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004;43:325–332. doi: 10.1016/j.jacc.2004.02.033

35. Pi J, Bai Y, Daniel KW, Liu D, Lyght O, Edelstein D, Brownlee M, Corkey BE, Collins S. Persistent oxidative stress due to absence of uncoupling protein 2 associated with impaired pancreatic beta-cell function. Endocrinology. 2009;150:3040–3048. doi: 10.1210/en.2008-1642

36. Zhang CY, Bafy G, Perret PK, Krauss S, Peroni O, Gruicj D, Hagen T, Vidal-Puig AJ, Boss O, Kim YB, et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell. 2011;145:745–755

37. Petersen KE, Dufour S, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350:664–671. doi: 10.1056/NEJMoa031314

38. Ryan JJ, Marsboom G, Fang YH, Toth PT, Morrow E, Luo N, Piao L, Lofaso F, Sciacqua A, Sbraccia P, Federici M, et al. PGC1alpha-mediated mitofusin-2 deficiency in male mice mimics the effects of hypoxia and mitochondrial protein hyperacetylation as disease model. Am J Respir Cell Mol Biol. 2020;45:900–910. doi: 10.1165/rcmb.2019-0006OC

39. Archer SL. Mitochondrial dynamics—mitochondrial fission and fusion in disease. Annu Rev Physiol. 2011;73:252–277. doi: 10.1146/annurev-physiol-022510-134113
SUPPLEMENTAL MATERIAL
**Figure S1.** A. Representative PCR blot confirming the genotype for the Sirt3 and Ucp2 mutant mice. Sirt3 mutant mice have deletion of exons 2-3. Based on the primer sequences used, the wild type allele shows at 562bp and the mutant allele shows at 200bp. The Sirt3 heterozygous mice are positive for both alleles (Top blot). The Ucp2 mutant mice have an insertion of a PGK-NEO cassette replacing exons 3-7 to create the larger mutant allele. The Ucp2 mutant allele shows at 280bp, while the wild type allele shows at 156bp. The Ucp2 heterozygous mice are positive for both alleles (bottom). B. qRT-PCR (in lung tissues) shows that the double knockout mice have no detectable levels of Sirt3 or Ucp2 mRNA, compared to wild type controls, while the double heterozygous mice express ~50% mRNA levels. C. Lung tissue from mice heterozygous or homozygous to the lack of both genes shows no detectable levels of either Sirt3 or Ucp2, and decreased expression of either SIRT3 or UCP2 compared to WT mice, using immunoblots. The remaining “smear” in the Ucp2 blot of Sirt3-/-Ucp2-/- mice, is likely due to the well-known cross-reactivity of the Ucp2 antibody with Ucp3, in all known commercially available antibodies (Ucp2 shares a 72% homology with Ucp3).
Figure S2. Representative LVEDP traces from anesthetized mice lacking Sirt3 and Ucp2 shows that they all have normal values.
Figure S3. Representative Masson’s trichrome pictures of right ventricles from Sirt3\(^{-/-}\)-Ucp2\(^{+/-}\) and Sirt3\(^{-/-}\)-Ucp2\(^{-/-}\) mice shows that they have a significant increase of fibrosis compared to WT mice. ****p<0.0001 (Kruskal-Wallis test) compared to WT mice, n=15 images from 3 mice / group.
**Figure S4.** Sixteen-month (12 months after developing PAH) Kaplan-Meier survival plot shows the Sirt3\(^{-/-}\)-Ucp2\(^{-/-}\) mice have decreased survival compared to WT mice. *p<0.05 compared to WT mice, n=16 mice / group.
**Figure S5.** Representative confocal immunohistochemistry images of pulmonary arteries from mice lacking Sirt3 and Ucp2 shows that they express higher levels of the proliferation marker Ki67 in their vascular wall.
Figure S6. Confocal immunohistochemistry of small pulmonary arteries (showing plexogenic lesions) as well as right heart catheterization data (pulmonary artery tracings and mean PA pressure data) shows normal pressures in 3 WT and 3 Sirt3−/−-Ucp2−/− 2 month-old mice, suggesting that the plexogenic arteriopathy is a very early event in the disease process.
Figure S7. Representative confocal immunohistochemistry images of small pulmonary arteries and mean data shows increased CD4+ T cells within and around the vascular wall of Sirt3−/−Ucp2+/−, and Sirt3−/−Ucp2−/− mice compared to WT mice. ****p<0.0001 (Bonferroni) compared to WT mice, n = 50 arteries / group.
**Figure S8.** Representative confocal immunohistochemistry images of PASMCs shows increased ratio of nuclear/cytoplasmic of Y705 p-STAT3 in PASMCs from mice lacking Sirt3 and Ucp2 compared to PASMCs from WT mice. ****p<0.0001 (Bonferroni) compared to WT mice, n = 60 cells / group (3 experiments).
**Figure S9.** Annexin V / Propidium Iodide (PI) staining of PASMCs exposed to serum starvation for 48 hours shows decreased apoptosis in the Sirt3⁻/⁻-Ucp2⁻/⁻ compared to the WT PASMCs. The cells stained only for Annexin V (marking apoptosis) and not PI (which marks death) are counted to measure apoptosis (and not necrosis). ****p<0.0001 (Mann-Whitney U test) compared to the WT PASMCs, n = ~240 cells / group (3 experiments).